PF-Atlas › Clinical Trials › NCT03919799
KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis
Belumosudil · Phase 2
Registry ID
NCT03919799
Phase
Phase 2
Status
Terminated
Drug / intervention
Belumosudil (KD025)
Sponsor
Kadmon, a Sanofi Company
Start
2019-06-26
About this trial
Belumosudil is evaluated in NCT03919799, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Kadmon, a Sanofi Company. Current status: Terminated.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT03919799 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.